Practice-Changing and Reaffirming Data Set Up an Exciting Future in Melanoma

Source: OncLive, November 2021

Positive data readouts from studies such as the phase 2/3 RELATIVITY-047 trial (NCT03470922) with relatlimab and nivolumab (Opdivo), and the phase 3 KEYNOTE-716 trial (NCT03553836) with pembrolizumab (Keytruda), cemented 2021 as a banner year for the treatment of patients with melanoma, across various stages and subtypes, according to Meredith McKean, MD, MPH.

Specifically, data from the RELATIVITY-047 concerned patients with untreated metastatic or unresectable melanoma who received a fixed-dose combination of the LAG3-blocking antibody relatlimab plus nivolumab or nivolumab alone. The data were stratified by mutational profiles including LAG3 expression on immune cells, PD-L1 expression on tumor cells, and BRAF status (TABLE).1 The KEYNOTE-716 data highlighted the use of pembrolizumab as adjuvant treatment for patients with resected high-risk stage II melanoma vs placebo.

READ THE ORIGINAL FULL ARTICLE
Menu